ReviewCurrent hypertension reports2017
Anti-angiogenesis and Preeclampsia in 2016.
Review in Current hypertension reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- METTL14 promotes trophoblast dysfunction by elevating SZRD1 expression in an m6A-dependent manner.Human cell · 2026Article
- NFĸB and its inhibitors in preeclampsia: mechanisms and potential interventions.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Impact of dietary salicylates on angiogenic factors and biochemical parameters in a rat model of preeclampsia.PloS one · 2025Article
- Diagnosis, Prevention, and Management of Fetal Growth Restriction (FGR).Journal of personalized medicine · 2024Review
- Literature Review: The sFlt1/PlGF Ratio and Pregestational Maternal Comorbidities: New Risk Factors to Predict Pre-Eclampsia.International journal of molecular sciences · 2023Review
- The Role of Syncytin in Placental Angiogenesis and Fetal Growth.Frontiers in cell and developmental biology · 2022Article
- Prediction of Differentially Expressed Genes and a Diagnostic Signature of Preeclampsia via Integrated Bioinformatics Analysis.Disease markers · 2022Article
- Identification of downstream targets and signaling pathways of long non-coding RNA NR_002794 in human trophoblast cells.Bioengineered · 2021Article
- HIV Associated Preeclampsia: A Multifactorial Appraisal.International journal of molecular sciences · 2021Review
- Unravelling the potential of angiogenic factors for the early prediction of preeclampsia.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Review
- Utility of biochemical tests in prediction, diagnostics and clinical management of preeclampsia: a review.Archives of medical science : AMS · 2020Article
- Circulating Tissue Inhibitor of Metalloproteinase-4 levels are not a Predictor of Preeclampsia in the period between 20 and 25 Weeks of Gestation.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2018Article
- Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of Bronchopulmonary Dysplasia.American journal of respiratory and critical care medicine · 2018Article
- Elevation of maternal serum sFlt-1 in pregnancy with mirror syndrome caused by fetal cardiac failure.Oxford medical case reports · 2018Article
- Impact of Preeclampsia on Clinical and Functional Outcomes in Women With Peripartum Cardiomyopathy.Circulation. Heart failure · 2017Article
- Serum NF-κBp65, TLR4 as Biomarker for Diagnosis of Preeclampsia.Open medicine (Warsaw, Poland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPreeclampsia remains one of the most important complications in pregnancy worldwide. With this review, we aim to give an overview on important research findings over the last years and their effects on current clinical management. RECENT
findingsThe association between preeclampsia and altered angiogenesis is nowadays widely accepted. Only during the last years, assessment of angiogenic factors such as the soluble fms-like tyrosine kinase-1-to-placental growth factor (sFlt-1/PlGF) ratio has become available to everyday clinical practice with commercially available automated measurements. With these, preeclampsia can be confirmed or ruled out in uncertainty of diagnosis, and a short-term prognosis can be given in patients with symptoms of preeclampsia. Pilot studies show that maternal serum levels of sFlt-1 can be reduced by therapeutic apheresis and that this might prolong pregnancy in case of very early severe preeclampsia. The automated measurement of the sFlt-1/PlGF ratio is starting to influence clinical management of preeclampsia. Apheresis might offer new treatment options, but still needs to be evaluated in randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.